Method Profile
Measure concentration-dependent drug response in bladder cancer organoids and compare a chemotherapy subset with postoperative follow-up.
Compare patient-derived tumor responses across chemotherapy regimens and disitamab vedotin.
Bladder tumor organoids generated from resected tissue; 19 cultures established and 12 completed drug testing among 22 enrolled patients.
ATP-associated viability after 72 hours, with IC50, curve area and maximum inhibition derived from concentration responses.
Patient material
Surgical bladder cancer tissue and matched tumor histology.
Treatment panel
Gemcitabine, cisplatin, epirubicin, pirarubicin, combinations and RC48/disitamab vedotin.
Response measurement
CellTiter-Glo 3D viability, with selected proliferation and apoptosis measurements.
Keep the number tested for each drug separate and distinguish postoperative chemotherapy concordance from the organoid-only ADC experiments.
Exploratory drug classification with a small postoperative comparison.
12 completed screens; 10 evaluable postoperative cases; RC48 tested in 4 organoid models.
Concentration responses and clinical regimens selected through usual care.
Nine of ten postoperative cases were concordant; one of four RC48-tested models was relatively sensitive.
A small bladder cancer study completed drug testing for 12 of 22 patients. Chemotherapy comparisons were linked with postoperative follow-up, while disitamab vedotin was evaluated only in organoids.
